<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05054257</url>
  </required_header>
  <id_info>
    <org_study_id>UHKT-CAR19-01</org_study_id>
    <secondary_id>2018-004789-32</secondary_id>
    <nct_id>NCT05054257</nct_id>
  </id_info>
  <brief_title>CART19 Cells Effects in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma</brief_title>
  <acronym>UHKT-CAR19-01</acronym>
  <official_title>Safety and Efficacy of Anti-CD19 Chimeric Antigen Receptor-modified Autologous T Cells (CART19) in Patients With Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma. A Dose Escalation, Open-label, Phase I Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institute of Hematology and Blood Transfusion, Czech Republic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institute of Hematology and Blood Transfusion, Czech Republic</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase I Dose Escalation Study of CART19 Cells for Adult Patients With Relapsed / Refractory&#xD;
      Acute Lymphoblastic Leukemia and Non-Hodgkin's Lymphoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, single arm study on up to 24 adult subjects with refractory or&#xD;
      relapsed CD19+ Non-Hodgkin's Lymphoma or B-ALL. Following lymphodepleting conditioning&#xD;
      regimen, the patients will receive a single dose of autologous CAR19 T lymphocytes provided&#xD;
      by the sponsor´s manufacturing facility. CART19 dose will be escalated in consecutive&#xD;
      patients using accelerated titration design in order to establish recommended CART19 dose for&#xD;
      further study, which will be either Maximum Tolerated Dose (MTD) or Maximum Feasible Dose&#xD;
      (MFD), whichever is reached first.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 2, 2021</start_date>
  <completion_date type="Anticipated">June 1, 2028</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2027</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of adverse events</measure>
    <time_frame>Up to 2 years post treatment</time_frame>
    <description>Cumulative incidence of IMP-related adverse events (AEs) graded by ASTCT consensus grading criteria for Cytokine Release Syndrome (CRS) and Immune effector cell-associated neurotoxicity syndrome (ICANS) and by Common Terminology Criteria for Adverse Events (CTCAE) v 5.0 for other AEs. Toxicities will be followed from the start of Blood Collection or Apheresis until the end of the study.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of Dose-Limiting Toxicities (DLTs)</measure>
    <time_frame>Up to 28 days after IMP administration</time_frame>
    <description>Incidence of Dose-limiting toxicities (DLTs) during the first 28 days after IMP administration</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete remission ( CR) rate</measure>
    <time_frame>CR rate at 100 days and 6 months after IMP administration</time_frame>
    <description>Assessment of the efficacy of IMP cells administration in patients with refractory or relapsed CD19+ NHL and B-ALL evaluated by Complete Remission rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>OS at 1 year after IMP administration</time_frame>
    <description>Assessment of the efficacy of IMP cells administration in patients with refractory or relapsed CD19+ NHL and B-ALL evaluated by Overall Survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life using the European Organization for the Research and Treatment of Cancer 30 item questionnaire (EORTC QLQ-C30).</measure>
    <time_frame>At 6 months and 1 year following IMP administration</time_frame>
    <description>EORTC-QLQ-C30 is a 30-item subject self-report questionnaire composed of both multi-item and single scales, including a global health status/quality of life (GHS/QoL) scale. Participants rate items on a four-point scale, with 1 as &quot;not at all&quot; and 4 as &quot;very much.&quot; A change of 5 - 10 points is considered a small. A change of 10 - 20 points is considered a moderate change.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>CART19 cells in peripheral blood, bone marrow and cerebrospinal fluid</measure>
    <time_frame>Up to 24 months</time_frame>
    <description>Assessment of quantity and phenotype of CART19 cells in peripheral blood, bone marrow and cerebrospinal fluid using using flow-cytometry</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia</condition>
  <condition>Non-Hodgkin's Lymphoma Refractory</condition>
  <condition>Non-Hodgkin's Lymphoma, Relapsed</condition>
  <arm_group>
    <arm_group_label>Autologous CAR19 T lymphocytes</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Human Autologous T Lymphocytes Expressing the Chimeric Antigen Receptor Specific to CD19</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Autologous CAR19 T lymphocytes</intervention_name>
    <description>First-in-human trial examining the safety and efficacy of CART19 in r/r B-ALL and B-NHL</description>
    <arm_group_label>Autologous CAR19 T lymphocytes</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patient with refractory or relapsing CD19 positive B-ALL or B-NHL defined as:&#xD;
&#xD;
               1. B-ALL refractory to treatment or in the second or subsequent relapse&#xD;
                  (hematological OR molecular), OR&#xD;
&#xD;
               2. B-NHL refractory to treatment or in first relapse ineligible for autologous stem&#xD;
                  cell transplantation (ASCT) or in second to fourth relapse, OR&#xD;
&#xD;
               3. B-ALL or B-NHL relapsing after autologous or allogeneic hematopoietic cell&#xD;
                  transplantation (HCT).&#xD;
&#xD;
          2. CD19 expression on malignant cells confirmed by flow cytometry or by&#xD;
             immunohistochemistry.&#xD;
&#xD;
          3. Age ≥18 years and &lt; 65 years.&#xD;
&#xD;
          4. Patient able to understand and sign informed consent.&#xD;
&#xD;
          5. Women of child-bearing potential: negative pregnancy test at enrolment (PSV) and at&#xD;
             Visit 1.&#xD;
&#xD;
        General Exclusion Criteria:&#xD;
&#xD;
          1. Known hypersensitivity to any component of the Investigational Medicinal Product&#xD;
             (IMP).&#xD;
&#xD;
          2. Autologous or allogeneic HCT in 3 months prior to IMP administration.&#xD;
&#xD;
          3. Vaccination with live virus vaccines in the 4 weeks before IMP administration and&#xD;
             within 90 days after the IMP dose.&#xD;
&#xD;
          4. Women: pregnancy or breast-feeding.&#xD;
&#xD;
          5. Subjects of fertile age, unless permanent sexual abstinence is their lifestyle choice:&#xD;
&#xD;
               -  female patients of childbearing potential not willing to use a highly effective&#xD;
                  method of contraception during the study,&#xD;
&#xD;
               -  male patients whose sexual partner(s) are women of childbearing potential who are&#xD;
                  not willing to use a highly effective method of contraception during the study.&#xD;
&#xD;
        Exclusion criteria to Procurement of IMP manufacture starting material&#xD;
&#xD;
          1. Severe uncontrolled active infection.&#xD;
&#xD;
          2. Positive test results for HIV1/2, Hepatitis B/C and lues.&#xD;
&#xD;
          3. Concurrent or recent prior therapies before apheresis:&#xD;
&#xD;
               -  Autologous or allogeneic hematopoietic cell transplantation within 12 weeks.&#xD;
&#xD;
               -  Clofarabine, Fludarabine, Alemtuzumab within 8 weeks.&#xD;
&#xD;
               -  Donor lymphocyte infusions within 4 weeks.&#xD;
&#xD;
               -  Pegylated asparaginase within 4 weeks.&#xD;
&#xD;
               -  Maintenance chemotherapy within 2 weeks.&#xD;
&#xD;
               -  Long-acting Granulocyte Colony Stimulating Factor (G-CSF) within 2 weeks.&#xD;
&#xD;
               -  Vincristine within 2 weeks.&#xD;
&#xD;
               -  Intrathecal methotrexate within 1 week.&#xD;
&#xD;
               -  Granulocyte Colony Stimulating Factor (G-CSF) within 5 days.&#xD;
&#xD;
               -  Therapeutic dose of corticosteroids within 3 days.&#xD;
&#xD;
               -  Short-acting cytostatics within 3 days&#xD;
&#xD;
        Exclusion criteria to IMP administration&#xD;
&#xD;
          1. Severe, uncontrolled active infections.&#xD;
&#xD;
          2. Life expectancy &lt; 6 weeks.&#xD;
&#xD;
          3. Parenchymal central nervous system involvement&#xD;
&#xD;
          4. Respiratory insufficiency (need for oxygen therapy).&#xD;
&#xD;
          5. Significant liver impairment: bilirubin &gt; 50 µmol/L, Aspartate aminotransferase (AST)&#xD;
             or Alanine aminotransferase (ALT) &gt; 4times normal upper limit.&#xD;
&#xD;
          6. Acute kidney injury with serum creatinine &gt; 180 µg/L, oliguria or dialysis.&#xD;
&#xD;
          7. Heart failure with Ejection Fraction (EF) &lt; 30% by echocardiography.&#xD;
&#xD;
          8. Presence of active grade 3 - 4 acute GvHD&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Petr Lesny</last_name>
    <role>Study Chair</role>
    <affiliation>Institute of Hematology and Blood Transfusion, Czech Republic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jan Vydra</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institute of Hematology and Blood Transfusion, Czech Republic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jan Vydra</last_name>
    <phone>+420221977182</phone>
    <email>jan.vydra@uhk.cz</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Petr Lesny</last_name>
    <phone>+420221977629</phone>
    <email>petr.lesny@uhkt.cz</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institute of Hematology and Blood Transfusion, Czech Republic</name>
      <address>
        <city>Prague</city>
        <zip>12800</zip>
        <country>Czechia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Vydra, MD</last_name>
      <phone>+420 221977182</phone>
      <email>jan.vydra@uhkt.cz</email>
    </contact>
    <contact_backup>
      <last_name>Petr Lesny, MD</last_name>
      <phone>+420221977629</phone>
      <email>petr.lesny@uhkt.cz</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Czechia</country>
  </location_countries>
  <reference>
    <citation>Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, Levine BL, June CH, Porter DL, Grupp SA. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med. 2014 Oct 16;371(16):1507-17. doi: 10.1056/NEJMoa1407222. Erratum in: N Engl J Med. 2016 Mar 10;374(10):998.</citation>
    <PMID>25317870</PMID>
  </reference>
  <reference>
    <citation>Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, Bagg A, Marcucci KT, Shen A, Gonzalez V, Ambrose D, Grupp SA, Chew A, Zheng Z, Milone MC, Levine BL, Melenhorst JJ, June CH. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015 Sep 2;7(303):303ra139. doi: 10.1126/scitranslmed.aac5415.</citation>
    <PMID>26333935</PMID>
  </reference>
  <reference>
    <citation>Hartmann J, Schüßler-Lenz M, Bondanza A, Buchholz CJ. Clinical development of CAR T cells-challenges and opportunities in translating innovative treatment concepts. EMBO Mol Med. 2017 Sep;9(9):1183-1197. doi: 10.15252/emmm.201607485. Review.</citation>
    <PMID>28765140</PMID>
  </reference>
  <reference>
    <citation>Hamada M, Nishio N, Okuno Y, Suzuki S, Kawashima N, Muramatsu H, Tsubota S, Wilson MH, Morita D, Kataoka S, Ichikawa D, Murakami N, Taniguchi R, Suzuki K, Kojima D, Sekiya Y, Nishikawa E, Narita A, Hama A, Kojima S, Nakazawa Y, Takahashi Y. Integration Mapping of piggyBac-Mediated CD19 Chimeric Antigen Receptor T Cells Analyzed by Novel Tagmentation-Assisted PCR. EBioMedicine. 2018 Aug;34:18-26. doi: 10.1016/j.ebiom.2018.07.008. Epub 2018 Aug 3.</citation>
    <PMID>30082227</PMID>
  </reference>
  <reference>
    <citation>Tipanee J, VandenDriessche T, Chuah MK. Transposons: Moving Forward from Preclinical Studies to Clinical Trials. Hum Gene Ther. 2017 Nov;28(11):1087-1104. doi: 10.1089/hum.2017.128. Epub 2017 Aug 22. Review.</citation>
    <PMID>28920716</PMID>
  </reference>
  <reference>
    <citation>Kebriaei P, Singh H, Huls MH, Figliola MJ, Bassett R, Olivares S, Jena B, Dawson MJ, Kumaresan PR, Su S, Maiti S, Dai J, Moriarity B, Forget MA, Senyukov V, Orozco A, Liu T, McCarty J, Jackson RN, Moyes JS, Rondon G, Qazilbash M, Ciurea S, Alousi A, Nieto Y, Rezvani K, Marin D, Popat U, Hosing C, Shpall EJ, Kantarjian H, Keating M, Wierda W, Do KA, Largaespada DA, Lee DA, Hackett PB, Champlin RE, Cooper LJ. Phase I trials using Sleeping Beauty to generate CD19-specific CAR T cells. J Clin Invest. 2016 Sep 1;126(9):3363-76. doi: 10.1172/JCI86721. Epub 2016 Aug 2.</citation>
    <PMID>27482888</PMID>
  </reference>
  <reference>
    <citation>Otáhal P, Průková D, Král V, Fabry M, Vočková P, Latečková L, Trněný M, Klener P. Lenalidomide enhances antitumor functions of chimeric antigen receptor modified T cells. Oncoimmunology. 2015 Dec 3;5(4):e1115940. eCollection 2016 Apr.</citation>
    <PMID>27141398</PMID>
  </reference>
  <reference>
    <citation>Yusa K, Zhou L, Li MA, Bradley A, Craig NL. A hyperactive piggyBac transposase for mammalian applications. Proc Natl Acad Sci U S A. 2011 Jan 25;108(4):1531-6. doi: 10.1073/pnas.1008322108. Epub 2011 Jan 4.</citation>
    <PMID>21205896</PMID>
  </reference>
  <reference>
    <citation>Ptáčková P, Musil J, Štach M, Lesný P, Němečková Š, Král V, Fábry M, Otáhal P. A new approach to CAR T-cell gene engineering and cultivation using piggyBac transposon in the presence of IL-4, IL-7 and IL-21. Cytotherapy. 2018 Apr;20(4):507-520. doi: 10.1016/j.jcyt.2017.10.001. Epub 2018 Feb 21.</citation>
    <PMID>29475789</PMID>
  </reference>
  <reference>
    <citation>Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D, Samanta M, Lakhal M, Gloss B, Danet-Desnoyers G, Campana D, Riley JL, Grupp SA, June CH. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther. 2009 Aug;17(8):1453-64. doi: 10.1038/mt.2009.83. Epub 2009 Apr 21. Erratum in: Mol Ther. 2015 Jul;23(7):1278.</citation>
    <PMID>19384291</PMID>
  </reference>
  <reference>
    <citation>Rivière I, Sadelain M. Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective. Mol Ther. 2017 May 3;25(5):1117-1124. doi: 10.1016/j.ymthe.2017.03.034. Epub 2017 Apr 26. Review.</citation>
    <PMID>28456379</PMID>
  </reference>
  <reference>
    <citation>Norelli M, Casucci M, Bonini C, Bondanza A. Clinical pharmacology of CAR-T cells: Linking cellular pharmacodynamics to pharmacokinetics and antitumor effects. Biochim Biophys Acta. 2016 Jan;1865(1):90-100. doi: 10.1016/j.bbcan.2015.12.001. Epub 2015 Dec 31. Review.</citation>
    <PMID>26748354</PMID>
  </reference>
  <reference>
    <citation>Lamers CH, Sleijfer S, van Steenbergen S, van Elzakker P, van Krimpen B, Groot C, Vulto A, den Bakker M, Oosterwijk E, Debets R, Gratama JW. Treatment of metastatic renal cell carcinoma with CAIX CAR-engineered T cells: clinical evaluation and management of on-target toxicity. Mol Ther. 2013 Apr;21(4):904-12. doi: 10.1038/mt.2013.17. Epub 2013 Feb 19.</citation>
    <PMID>23423337</PMID>
  </reference>
  <reference>
    <citation>Till BG, Jensen MC, Wang J, Chen EY, Wood BL, Greisman HA, Qian X, James SE, Raubitschek A, Forman SJ, Gopal AK, Pagel JM, Lindgren CG, Greenberg PD, Riddell SR, Press OW. Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells. Blood. 2008 Sep 15;112(6):2261-71. doi: 10.1182/blood-2007-12-128843. Epub 2008 May 28.</citation>
    <PMID>18509084</PMID>
  </reference>
  <reference>
    <citation>Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med. 2011 Aug 25;365(8):725-33. doi: 10.1056/NEJMoa1103849. Epub 2011 Aug 10. Erratum in: N Engl J Med. 2016 Mar 10;374(10):998.</citation>
    <PMID>21830940</PMID>
  </reference>
  <reference>
    <citation>Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, Sommermeyer D, Melville K, Pender B, Budiarto TM, Robinson E, Steevens NN, Chaney C, Soma L, Chen X, Yeung C, Wood B, Li D, Cao J, Heimfeld S, Jensen MC, Riddell SR, Maloney DG. CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients. J Clin Invest. 2016 Jun 1;126(6):2123-38. doi: 10.1172/JCI85309. Epub 2016 Apr 25.</citation>
    <PMID>27111235</PMID>
  </reference>
  <reference>
    <citation>Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS, Stefanski J, Borquez-Ojeda O, Olszewska M, Qu J, Wasielewska T, He Q, Fink M, Shinglot H, Youssif M, Satter M, Wang Y, Hosey J, Quintanilla H, Halton E, Bernal Y, Bouhassira DC, Arcila ME, Gonen M, Roboz GJ, Maslak P, Douer D, Frattini MG, Giralt S, Sadelain M, Brentjens R. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014 Feb 19;6(224):224ra25. doi: 10.1126/scitranslmed.3008226.</citation>
    <PMID>24553386</PMID>
  </reference>
  <reference>
    <citation>Mueller KT, Waldron E, Grupp SA, Levine JE, Laetsch TW, Pulsipher MA, Boyer MW, August KJ, Hamilton J, Awasthi R, Stein AM, Sickert D, Chakraborty A, Levine BL, June CH, Tomassian L, Shah SS, Leung M, Taran T, Wood PA, Maude SL. Clinical Pharmacology of Tisagenlecleucel in B-cell Acute Lymphoblastic Leukemia. Clin Cancer Res. 2018 Dec 15;24(24):6175-6184. doi: 10.1158/1078-0432.CCR-18-0758. Epub 2018 Sep 6.</citation>
    <PMID>30190371</PMID>
  </reference>
  <reference>
    <citation>Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuirk JP, Jäger U, Jaglowski S, Andreadis C, Westin JR, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Pantano S, Pacaud LB, Awasthi R, Chu J, Anak Ö, Salles G, Maziarz RT; JULIET Investigators. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. N Engl J Med. 2019 Jan 3;380(1):45-56. doi: 10.1056/NEJMoa1804980. Epub 2018 Dec 1.</citation>
    <PMID>30501490</PMID>
  </reference>
  <reference>
    <citation>Singh H, Figliola MJ, Dawson MJ, Olivares S, Zhang L, Yang G, Maiti S, Manuri P, Senyukov V, Jena B, Kebriaei P, Champlin RE, Huls H, Cooper LJ. Manufacture of clinical-grade CD19-specific T cells stably expressing chimeric antigen receptor using Sleeping Beauty system and artificial antigen presenting cells. PLoS One. 2013 May 31;8(5):e64138. doi: 10.1371/journal.pone.0064138. Print 2013.</citation>
    <PMID>23741305</PMID>
  </reference>
  <reference>
    <citation>Simon R, Freidlin B, Rubinstein L, Arbuck SG, Collins J, Christian MC. Accelerated titration designs for phase I clinical trials in oncology. J Natl Cancer Inst. 1997 Aug 6;89(15):1138-47.</citation>
    <PMID>9262252</PMID>
  </reference>
  <reference>
    <citation>Kershaw MH, Westwood JA, Parker LL, Wang G, Eshhar Z, Mavroukakis SA, White DE, Wunderlich JR, Canevari S, Rogers-Freezer L, Chen CC, Yang JC, Rosenberg SA, Hwu P. A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer. Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6106-15.</citation>
    <PMID>17062687</PMID>
  </reference>
  <reference>
    <citation>Park JR, Digiusto DL, Slovak M, Wright C, Naranjo A, Wagner J, Meechoovet HB, Bautista C, Chang WC, Ostberg JR, Jensen MC. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther. 2007 Apr;15(4):825-33. Epub 2007 Feb 13.</citation>
    <PMID>17299405</PMID>
  </reference>
  <reference>
    <citation>Kochenderfer JN, Dudley ME, Kassim SH, Somerville RP, Carpenter RO, Stetler-Stevenson M, Yang JC, Phan GQ, Hughes MS, Sherry RM, Raffeld M, Feldman S, Lu L, Li YF, Ngo LT, Goy A, Feldman T, Spaner DE, Wang ML, Chen CC, Kranick SM, Nath A, Nathan DA, Morton KE, Toomey MA, Rosenberg SA. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol. 2015 Feb 20;33(6):540-9. doi: 10.1200/JCO.2014.56.2025. Epub 2014 Aug 25.</citation>
    <PMID>25154820</PMID>
  </reference>
  <reference>
    <citation>Kochenderfer JN, Dudley ME, Feldman SA, Wilson WH, Spaner DE, Maric I, Stetler-Stevenson M, Phan GQ, Hughes MS, Sherry RM, Yang JC, Kammula US, Devillier L, Carpenter R, Nathan DA, Morgan RA, Laurencot C, Rosenberg SA. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood. 2012 Mar 22;119(12):2709-20. doi: 10.1182/blood-2011-10-384388. Epub 2011 Dec 8.</citation>
    <PMID>22160384</PMID>
  </reference>
  <reference>
    <citation>Hay KA, Hanafi LA, Li D, Gust J, Liles WC, Wurfel MM, López JA, Chen J, Chung D, Harju-Baker S, Cherian S, Chen X, Riddell SR, Maloney DG, Turtle CJ. Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor-modified T-cell therapy. Blood. 2017 Nov 23;130(21):2295-2306. doi: 10.1182/blood-2017-06-793141. Epub 2017 Sep 18.</citation>
    <PMID>28924019</PMID>
  </reference>
  <reference>
    <citation>Comerota AJ, Throm RC, Miller KA, Henry T, Chronos N, Laird J, Sequeira R, Kent CK, Bacchetta M, Goldman C, Salenius JP, Schmieder FA, Pilsudski R. Naked plasmid DNA encoding fibroblast growth factor type 1 for the treatment of end-stage unreconstructible lower extremity ischemia: preliminary results of a phase I trial. J Vasc Surg. 2002 May;35(5):930-6.</citation>
    <PMID>12021709</PMID>
  </reference>
  <reference>
    <citation>Powell RJ, Simons M, Mendelsohn FO, Daniel G, Henry TD, Koga M, Morishita R, Annex BH. Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia. Circulation. 2008 Jul 1;118(1):58-65. doi: 10.1161/CIRCULATIONAHA.107.727347. Epub 2008 Jun 16.</citation>
    <PMID>18559703</PMID>
  </reference>
  <reference>
    <citation>Gonin P, Gaillard C. Gene transfer vector biodistribution: pivotal safety studies in clinical gene therapy development. Gene Ther. 2004 Oct;11 Suppl 1:S98-S108. Review.</citation>
    <PMID>15454964</PMID>
  </reference>
  <reference>
    <citation>Dotti G. T lymphocytes are not immune. Mol Ther. 2013 Jun;21(6):1114-5. doi: 10.1038/mt.2013.102.</citation>
    <PMID>23728254</PMID>
  </reference>
  <reference>
    <citation>Saha S, Woodard LE, Charron EM, Welch RC, Rooney CM, Wilson MH. Evaluating the potential for undesired genomic effects of the piggyBac transposon system in human cells. Nucleic Acids Res. 2015 Feb 18;43(3):1770-82. doi: 10.1093/nar/gkv017. Epub 2015 Jan 20.</citation>
    <PMID>25605795</PMID>
  </reference>
  <reference>
    <citation>Heinrich T, Rengstl B, Muik A, Petkova M, Schmid F, Wistinghausen R, Warner K, Crispatzu G, Hansmann ML, Herling M, von Laer D, Newrzela S. Mature T-cell lymphomagenesis induced by retroviral insertional activation of Janus kinase 1. Mol Ther. 2013 Jun;21(6):1160-8. doi: 10.1038/mt.2013.67. Epub 2013 Apr 23.</citation>
    <PMID>23609016</PMID>
  </reference>
  <reference>
    <citation>Hacein-Bey-Abina S, von Kalle C, Schmidt M, Le Deist F, Wulffraat N, McIntyre E, Radford I, Villeval JL, Fraser CC, Cavazzana-Calvo M, Fischer A. A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. N Engl J Med. 2003 Jan 16;348(3):255-6.</citation>
    <PMID>12529469</PMID>
  </reference>
  <reference>
    <citation>Wang W, Lin C, Lu D, Ning Z, Cox T, Melvin D, Wang X, Bradley A, Liu P. Chromosomal transposition of PiggyBac in mouse embryonic stem cells. Proc Natl Acad Sci U S A. 2008 Jul 8;105(27):9290-5. doi: 10.1073/pnas.0801017105. Epub 2008 Jun 25.</citation>
    <PMID>18579772</PMID>
  </reference>
  <reference>
    <citation>Rad R, Rad L, Wang W, Cadinanos J, Vassiliou G, Rice S, Campos LS, Yusa K, Banerjee R, Li MA, de la Rosa J, Strong A, Lu D, Ellis P, Conte N, Yang FT, Liu P, Bradley A. PiggyBac transposon mutagenesis: a tool for cancer gene discovery in mice. Science. 2010 Nov 19;330(6007):1104-7. doi: 10.1126/science.1193004. Epub 2010 Oct 14.</citation>
    <PMID>20947725</PMID>
  </reference>
  <reference>
    <citation>Fedoroff NV. Presidential address. Transposable elements, epigenetics, and genome evolution. Science. 2012 Nov 9;338(6108):758-67.</citation>
    <PMID>23145453</PMID>
  </reference>
  <reference>
    <citation>Hackett PB, Largaespada DA, Switzer KC, Cooper LJ. Evaluating risks of insertional mutagenesis by DNA transposons in gene therapy. Transl Res. 2013 Apr;161(4):265-83. doi: 10.1016/j.trsl.2012.12.005. Epub 2013 Jan 10. Review.</citation>
    <PMID>23313630</PMID>
  </reference>
  <reference>
    <citation>Zhao S, Jiang E, Chen S, Gu Y, Shangguan AJ, Lv T, Luo L, Yu Z. PiggyBac transposon vectors: the tools of the human gene encoding. Transl Lung Cancer Res. 2016 Feb;5(1):120-5. doi: 10.3978/j.issn.2218-6751.2016.01.05. Review.</citation>
    <PMID>26958506</PMID>
  </reference>
  <reference>
    <citation>Fraietta JA, Lacey SF, Orlando EJ, Pruteanu-Malinici I, Gohil M, Lundh S, Boesteanu AC, Wang Y, O'Connor RS, Hwang WT, Pequignot E, Ambrose DE, Zhang C, Wilcox N, Bedoya F, Dorfmeier C, Chen F, Tian L, Parakandi H, Gupta M, Young RM, Johnson FB, Kulikovskaya I, Liu L, Xu J, Kassim SH, Davis MM, Levine BL, Frey NV, Siegel DL, Huang AC, Wherry EJ, Bitter H, Brogdon JL, Porter DL, June CH, Melenhorst JJ. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat Med. 2018 May;24(5):563-571. doi: 10.1038/s41591-018-0010-1. Epub 2018 Apr 30. Erratum in: Nat Med. 2021 Mar;27(3):561.</citation>
    <PMID>29713085</PMID>
  </reference>
  <reference>
    <citation>Milone MC, Bhoj VG. The Pharmacology of T Cell Therapies. Mol Ther Methods Clin Dev. 2018 Jan 31;8:210-221. doi: 10.1016/j.omtm.2018.01.010. eCollection 2018 Mar 16. Review.</citation>
    <PMID>29552577</PMID>
  </reference>
  <reference>
    <citation>Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, Bader P, Verneris MR, Stefanski HE, Myers GD, Qayed M, De Moerloose B, Hiramatsu H, Schlis K, Davis KL, Martin PL, Nemecek ER, Yanik GA, Peters C, Baruchel A, Boissel N, Mechinaud F, Balduzzi A, Krueger J, June CH, Levine BL, Wood P, Taran T, Leung M, Mueller KT, Zhang Y, Sen K, Lebwohl D, Pulsipher MA, Grupp SA. Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia. N Engl J Med. 2018 Feb 1;378(5):439-448. doi: 10.1056/NEJMoa1709866.</citation>
    <PMID>29385370</PMID>
  </reference>
  <reference>
    <citation>Lee DW, Santomasso BD, Locke FL, Ghobadi A, Turtle CJ, Brudno JN, Maus MV, Park JH, Mead E, Pavletic S, Go WY, Eldjerou L, Gardner RA, Frey N, Curran KJ, Peggs K, Pasquini M, DiPersio JF, van den Brink MRM, Komanduri KV, Grupp SA, Neelapu SS. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells. Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638. doi: 10.1016/j.bbmt.2018.12.758. Epub 2018 Dec 25. Review.</citation>
    <PMID>30592986</PMID>
  </reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 19, 2021</study_first_submitted>
  <study_first_submitted_qc>September 13, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2021</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>B Cell</keyword>
  <keyword>ALL</keyword>
  <keyword>Relapsed or Refractory</keyword>
  <keyword>B-NHL</keyword>
  <keyword>Leukemia</keyword>
  <keyword>Chimeric antigen receptor</keyword>
  <keyword>CAR</keyword>
  <keyword>CAR T cell</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
    <mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

